Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework

University of Vermont

Status: Completed

Conditions: Drug-Induced Movement Disorder

Treatments: Other: In-person Consult; Other: Telemedicine Consult

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT06060444

STUDY00001579

Details and patient eligibility

About

In this pilot study, the investigators will evaluate care delivery via telemedicine to individuals with drug-induced movement disorders (DIMDs). DIMDs can be disabling, and prevention is important; but these disorders are often under-reported, under-recognized and poorly managed. Interprofessional telemedicine for movement disorders is feasible and may provide similar care as in-person visits; however, the majority of studies to date have shown benefit in Parkinson's disease and further validation in other movement disorders is necessary.

In this randomized controlled trial the aim is to study the acceptability, feasibility, and patient and clinician outcomes when a neurological consultation is provided for patients with DIMDs either in-person or through telemedicine. The investigators will apply the evaluation framework RE-AIM (Reach and Effectiveness, Adoption, Implementation, and Maintenance) to comprehensively assess the factors that may impact study success and program implementation. Mixed methods will be implemented to gather outcome data from mental health clinicians that refer patients and the patient participants.

Enrollment: 28 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years or older
• Willing and able to provide consent
• Willing to have their Mental Health Clinician (MHC) share sensitive clinical information with the Neurology team
• Able to travel to Neurology clinic
• Have connectivity to Zoom using wi-fi or cellular data, either at home or a comfortable and private setting (such as MHC office)

Exclusion criteria

• Currently hospitalized
• Neurologist determines patient requires care outside of the scope of the study

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

28 participants in 2 patient groups

In-Person

Other group

Description:

Control group

Treatment:

Other: In-person Consult

Telemedicine

Experimental group

Treatment:

Other: Telemedicine Consult